GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fagron SA (OTCPK:ARSUF) » Definitions » Return-on-Tangible-Equity

ARSUF (Fagron) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Fagron Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fagron's annualized net income for the quarter that ended in Dec. 2024 was $84.0 Mil. Fagron's average shareholder tangible equity for the quarter that ended in Dec. 2024 was $-16.4 Mil. Therefore, Fagron's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was Negative Tangible Equity%.

The historical rank and industry rank for Fagron's Return-on-Tangible-Equity or its related term are showing as below:

ARSUF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: Negative Tangible Equity

ARSUF's Return-on-Tangible-Equity is ranked better than
99.89% of 906 companies
in the Drug Manufacturers industry
Industry Median: 6.39 vs ARSUF: Negative Tangible Equity

Fagron Return-on-Tangible-Equity Historical Data

The historical data trend for Fagron's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fagron Return-on-Tangible-Equity Chart

Fagron Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Fagron Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Competitive Comparison of Fagron's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Fagron's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fagron's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fagron's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Fagron's Return-on-Tangible-Equity falls into.


;
;

Fagron Return-on-Tangible-Equity Calculation

Fagron's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=84.35/( (-20.937+-7.317 )/ 2 )
=84.35/-14.127
=Negative Tangible Equity %

Fagron's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=84.038/( (-25.508+-7.317)/ 2 )
=84.038/-16.4125
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Fagron  (OTCPK:ARSUF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Fagron Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Fagron's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Fagron Business Description

Traded in Other Exchanges
Address
Fascinatio Boulevard 350, Rotterdam, ZH, NLD, 3065 WB
Fagron SA is a pharmaceutical compounding company operating in Belgium. It acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company also produces pharmaceutical raw materials, equipment, and supplies that are needed to prepare medication in the pharmacy. Its segments are namely Fagron Europe, Middle East and Africa (EMEA), Fagron North America, and Fagron Latin America. The majority of its revenue comes from Fagron North America.

Fagron Headlines

From GuruFocus

Q2 2022 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2020 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2022 Fagron NV Trading Statement Call Transcript

By GuruFocus Research 02-12-2024

Full Year 2019 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2021 Fagron NV Trading Statement Call Transcript

By GuruFocus Research 02-12-2024

Fagron NV At Capital Markets Day Transcript

By GuruFocus Research 02-12-2024

Q2 2019 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2023 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2022 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2021 Fagron NV Earnings Presentation Transcript

By GuruFocus Research 02-12-2024